Gonadotropin Releasing Hormone (GnRH) Therapy Notification
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage, medical necessity criteria, restricted products, dosing/HCPCS units, duration limits, and site-of-care considerations for GnRH (leuprolide, triptorelin, histrelin, goserelin) therapies for Blue Cross Blue Shield North Carolina members.
Added Site of Care medical necessity criteria for Camcevi, Camcevi ETM, Eligard, Vabrinty, Leuprolide Depot, Lutrate Depot, Lupron Depot Kit, and Lupron Depot-Ped Kit.
Added maximum units within dosing table specific to off-label indications for applicable products.
Adjusted criteria for off-label indications to remove products without sufficient clinical evidence.
Noted that leuprolide acetate for subcutaneous injection (HCPCS J9218) is a self-administered pharmacy benefit product and may be subject to pharmacy benefit restrictions.
For gender identity disorder/gender dysphoria indications, requirement added that patient has sex trait modification coverage and a benefits limitation statement was included.
Added HCPCS code J9003 for Camcevi ETM and removed temporary miscellaneous codes (C9399, J3490, J3590, J9999) effective 4/1/2026.
Coverage and Medical Necessity Criteria
Indication-specific medical necessity
Covered when ALL of the following indication-specific criteria are met per listed agents:
Indication-specific agent mapping
- Breast cancer: Patient has diagnosis of breast cancer AND the requested agent is one of: Eligard or Vabrinty (leuprolide) [J9217]; OR Lupron Depot kits (7.5, 22.5, 30, 45 mg) [J9217]; OR Trelstar (triptorelin) [J3315]; OR Zoladex (goserelin) [J9202]; OR Lupron Depot 3.75 mg or 11.25 mg kits [J1950].
chunk 6
- Endometriosis: Patient has diagnosis of endometriosis AND BOTH: (a) the requested agent is Zoladex (goserelin) [J9202] OR Lupron Depot 3.75 mg or 11.25 mg kits or Lupron Depot-Ped Kit [J1950]; AND (b) for all requests either patient is treatment-naive to the requested agent OR if previously treated, additional subcriteria (documented months completed and retreatment rules) are satisfied per policy.
chunks 6 and 10
- Gender identity disorder / Gender dysphoria / Gender incongruence: Patient has diagnosis and the member has coverage for sex trait modification AND the requested agent is one of: Eligard/Vabrinty [J9217]; OR Lupron Depot 7.5/22.5/30/45 mg kits [J9217]; OR Lupron Depot 3.75/11.25 mg kits or Lupron Depot-Ped Kit [J1950]; OR Triptodur [J3316]; OR Supprelin LA [J9226]; OR Zoladex [J9202].
chunk 8
- Prostate cancer: Patient has diagnosis of prostate cancer AND the requested agent is one of: Eligard/Vabrinty [J9217]; OR Lupron Depot 7.5/22.5/30/45 mg kits [J9217]; OR Trelstar [J3315]; OR Zoladex [J9202]; OR Camcevi [J1952]; OR Camcevi ETM [J9003]; OR Lupron Depot 3.75/11.25 mg kits [J1950]; OR generic Leuprolide Depot/Lutrate [J1954].
chunks 8-9
- Other FDA-approved or compendia-supported indications: Patient has another FDA-approved indication OR the indication is supported by compendia/NCCN per policy (documentation required) and requested dosing/quantity/duration are within FDA/NCCN/compendia limits.
chunk 10
Duration of therapy
Duration limits and lifetime caps
chunk 12
Safety limits
Safety and re-treatment constraints
chunks 3 and 17
Site-of-care requirement
Site of care
chunk 11
Site of Care Criteria
Administration setting covered when ALL of the following are met:
chunk 22
Outpatient hospital administration
- Severe adverse event history: History of a severe adverse event following the injection/infusion (anaphylaxis, seizure, thromboembolism, myocardial infarction, renal failure).
chunk 22
- Increased risk conditions: Conditions that cause increased risk for severe adverse event (unstable renal function, cardiopulmonary conditions, unstable vascular access).
chunk 22
- Unmanaged mild adverse events: History of mild adverse events not managed by mild pre-medication (diphenhydramine, acetaminophen, steroids, fluids).
chunk 22
- Adherence inability: Inability to physically and cognitively adhere to treatment schedule and regimen complexity.
chunk 22
- New to therapy defined as initial injection/infusion OR less than 3 months since initial injection/infusion.
chunk 22
- Re-initiation defined as first injection after 6 months off for drugs with <6-month dosing interval OR first injection after ≥1 month gap outside approved 6-month dosing interval.
chunk 22
- Change in formulation: Requirement of a change in the requested restricted product formulation.
chunk 22
General coverage requirements
Coverage and dosing must align with FDA label or NCCN compendia 1 or 2A when applicable; maximum units and product-specific HCPCS must be followed.
chunks 10, 24, 23
chunk 23
Some member benefit plans may specifically exclude coverage for drugs used for sex trait modification (gender‑affirming care). Coverage availability and any applicable limitations vary by state and by the member's specific benefit plan. Always check the Member's Benefit Booklet and applicable state law to determine whether sex trait modification therapies are covered for the member.
Drugs used for sex trait modification (gender‑affirming care) may be specifically excluded under some health benefit plans. When benefits for these therapies are available, the policy requires that the patient have plan coverage for sex trait modification before authorization can be considered; refer to the Member's Benefit Booklet for benefit availability and plan‑specific limitations.
Leuprolide acetate for subcutaneous injection (HCPCS J9218) is a self‑administered product supplied under the pharmacy channel. As noted in the policy, J9218 is covered under the pharmacy benefit only and may be subject to the member's pharmacy benefit coverage restrictions. Verify pharmacy‑benefit rules and prior authorization requirements when J9218 is requested.
Inpatient administration is permitted only when the admission meets medical necessity beyond solely receiving the injection or infusion. Specifically, the policy states that an injection/infusion may be given during an inpatient stay if medical necessity criteria are met and the inpatient admission is not solely for administration of the injection/infusion. Requests where the admission is solely for the injection/infusion are not supported as medically necessary.
HCPCS / Coding and Maximum Units
| J1952 | leuprolide mesylate (Camcevi) subcutaneous injection (Camcevi) HCPCS (listed in notes) |
| J9003 | leuprolide mesylate (Camcevi ETM) HCPCS |
| J9217 | leuprolide acetate (Eligard/Vabrinty) HCPCS |
| J1950 | leuprolide acetate (Lupron Depot 3.75 mg / 11.25 mg) HCPCS |
| J1951 | leuprolide acetate (Fensolvi) HCPCS |
| J1954 | leuprolide acetate generic Leuprolide Depot / Lutrate Depot HCPCS |
| J3315 | triptorelin pamoate (Trelstar) HCPCS |
| J3316 | triptorelin (Triptodur) HCPCS |
| J9226 | histrelin acetate (Supprelin LA) HCPCS |
| J9202 | goserelin acetate (Zoladex) HCPCS |
| J1950 | leuprolide acetate for depot suspension (Lupron Depot- Ped Kit) IM injection |
| J9226 | histrelin acetate (Supprelin LA) SC implant |
| J3315 | triptorelin pamoate (Trelstar) IM injection |
| J3316 | triptorelin pamoate (Triptodur) extended-release IM injection |
| J9202 | goserelin acetate (Zoladex) SC implant |
| J9003 | Camcevi ETM (leuprolide) — 1 unit per 1 mg |
Prior Authorization, Documentation, and Billing Actions
Prior Authorization Required
Prior authorization is required for restricted products. Prescribers must request authorization before dispensing or administering listed agents (e.g., leuprolide products, triptorelin, histrelin, etc.).
- Prior authorization required for restricted products; prescriber must document diagnosis and meet criteria
Nonconcordant Dosing / Compendia Support
Requests with dosing, quantity, or duration that do not match FDA-labeled dosing/maximum units for the requested indication or lack compendia (e.g., NCCN 1 or 2A, AHFS, DrugDex 1 or 2A) support may be denied. For oncologic indications the requested dose/duration must be within FDA label or NCCN 1/2A supported dosing. For non-oncologic indications, requests must not exceed maximum units allowed for the duration of approval.
- Nonconcordant dosing/compendia support — requests not meeting FDA labeled dosing/quantity/duration or lacking compendia/NCCN support may be denied
- For oncologic indications: FDA label OR NCCN 1 or 2A dosing required; for non-oncologic: do not exceed specified maximum units
Site-of-Care Noncompliance
If the request is for inpatient or outpatient hospital administration of specified products (e.g., Camcevi, Camcevi ETM, Eligard, Vabrinty, Leuprolide Depot Kit, Lutrate Depot, Lupron Depot Kit, Lupron Depot-Ped Kit), Site-of-Care criteria apply. Requests for inpatient admission solely for the purpose of administering an injection/infusion may be denied.
- Site-of-care criteria apply to specified products for hospital-based administration
- Inpatient admission may be denied if the sole purpose is to administer the injection/infusion
Medical Record Documentation Required
Medical record documentation must be provided with the prior authorization request. The prescriber must document the diagnosis, supporting clinical information, and the total number of months the patient has completed on therapy.
- Medical record documentation required — prescriber must provide diagnosis and supporting records
- Prescriber must provide total months on therapy
Documentation to Justify Site-of-Care Setting
When requesting hospital outpatient administration, the prescriber must document why the site-of-care is medically necessary. Acceptable justification includes history of severe adverse event(s) to the drug, conditions increasing risk for severe events, unsuccessful management of prior mild reactions with pre-medication, inability to adhere to outpatient regimen, new-to-therapy or recent re-initiation per policy definitions, or need to change formulation.
- Documentation to justify site-of-care setting — history of severe adverse events (e.g., anaphylaxis), increased clinical risk, failed pre-medication management, adherence limitations, new-to-therapy or re-initiation criteria, requirement for formulation change
Compendia / NCCN Support Requirements
Compendia or NCCN support is required for non‑FDA labelled (off‑label) uses or to meet dosing exceptions. For oncologic off‑label uses, NCCN 1 or 2A recommended use (including all requirements in the 'Recommended Use' box) is required. For non‑oncologic off‑label uses, support from AHFS, DrugDex (1 or 2A), or NCCN 1 or 2A is required.
- Compendia/NCCN support requirements — NCCN 1 or 2A for oncologic indications; AHFS or DrugDex 1/2A or NCCN 1/2A for non-oncologic indications
- Medical record documentation required to demonstrate compendia/NCCN support
Step / Criteria for Off‑Label Indications
Off‑label indications require stepwise documentation and may require prior trials or failures per product-specific criteria. Approvals for off‑label uses must meet the policy's compendia/NCCN support rules and any additional product-specific steps (for example, prior treatment trials, documented rationale, or limits on maximum units/duration).
- Step/criteria for off-label indications — follow product-specific criteria and compendia/NCCN support
- Off-label approvals may require prior failures, documented rationale, and adherence to maximum units for the indication
Initial Authorization Requirements
Initial therapy criteria
Initial authorization requirements
chunks 6, 8, 10
Initial therapy
Initial dosing per FDA label referenced in dosing table; pediatric and adult formulations vary by weight, dose, and interval.
chunk 18
chunk 18
chunk 20
Continuation and Retreatment
Continuation/retreatment
Continuation and retreatment rules
chunks 8, 17, 12
Continuation therapy
Continuation/maintenance dosing follows product labeling (repeat intervals and discontinuation guidance).
chunk 18
chunk 18
Step Therapy and Prior Treatments
| Step | Requirement | Evidence / Documentation Required |
|---|---|---|
| 1 | ||
| Documentation of compendia/NCCN support is required prior to approval | ||
| Medical record documentation that the indication is FDA‑approved for the requested agent or that the indication is supported by NCCN (oncologic indications: NCCN 1 or 2A 'Recommended Use' with all requirements met) or compendia (non‑oncologic: AHFS, DrugDex 1 or 2A). |
| Step | Policy change / applicability | Provider action |
|---|---|---|
| 1 | ||
| Adjusted product applicability for off‑label uses; coding updates and product‑specific criteria were added/clarified (see policy implementation notes). | ||
| Follow the updated product‑specific criteria and coding before switching or stepping to alternate products; ensure requested HCPCS matches the product and that any off‑label request meets the revised evidence requirements. |
Product Quantity Limits and Maximum Units
Site-of-Care Medical Necessity Rules
Site‑of‑care rules for listed injection/infusion agents
Site‑of‑Care criteria apply for requests for injection/infusion administration of Camcevi, Camcevi ETM, Eligard, Vabrinty, Lupron Depot kits — administration settings include office, infusion center, or hospital outpatient but hospital settings require site‑of‑care medical necessity documentation.
Site‑of‑care medical necessity criteria and applicable exclusions
Site‑of‑care medical necessity criteria apply to hospital outpatient/home/office settings for applicable agents; these Site‑of‑Care rules are NOT applicable to Fensolvi, Supprelin LA, Trelstar, Triptodur, and Zoladex — if criteria are not met, administration should occur in home infusion or physician office.
Background and Definitions
Gonadotropin‑releasing hormone (GnRH) agonists — including leuprolide, triptorelin, histrelin, and goserelin — are used to suppress sex hormone production for multiple clinical indications such as prostate and breast cancers, central precocious puberty (CPP) in pediatric patients, endometriosis, uterine fibroids (preoperative use), and certain gender dysphoria indications when covered by the member's plan. Many formulations are depot injections or implants with indication‑specific dosing intervals and duration limits; some agents carry safety considerations (for example, bone mineral density loss with prolonged therapy) that influence retreatment and lifetime duration limits.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.